Ashley Gallagher is an assistant editor at Pharmacy Times®. She graduated from St. Bonaventure University in 2020 in journalism and mass communications. Previously, she worked as a pharmacy technician for a retail chain.
Enfortumab Vedotin, Pembrolizumab Combo Maintains Strong Objective Response Rate Treating Urothelial Cancer
The drug combination demonstrated a 64.5% confirmed objective response rate in individuals with unresectable locally advanced or metastatic urothelial cancer who are ineligible to receive cisplatin-based chemotherapy.
FDA Accepts sBLA of Trastuzumab Deruxtecan for Treatment of Individuals With HER2-Low Breast Cancer
Trastuzumab deruxtecan is an engineered HER2-directed antibody drug conjugate being jointly developed and commercialized by AstraZeneca and Daiichi Sankyo.
Additional COVID-19 Booster Dose Strengthens Waning Immunity Against Omicron Subvariants
Study findings coincide with the US government considering recommendations of a second COVID-19 booster dose for adults under 50 years of age.
Illinois Bill Allows Pharmacists to Prescribe HIV Pre-, Post-Exposure Prophylaxis Drugs, Testing
The bill allows pharmacists to dispense and administer drugs, order laboratory tests, and consult patients on HIV pre- and post-exposure drugs.
Study: Pregnant African Women With COVID-19 Have Double Risk of ICU Admission
Results of analysis also show they have a much higher incidence of dying in the hospital than those without the virus.
Study: COVID-19 Pandemic Leads to Decrease in HIV-Related Services in India
The numbers dropped sharply in March 2020 from before the pandemic among men who have sex with men and individuals who inject drugs.
Study Results Indicate Increase in Early-Onset Colorectal Cancer
Delayed diagnosis in younger individuals and presentation of advanced disease highlights need for awareness.
Vitamin B6 Supplements Reduces Anxiety, Depression in New Study
Participants took about 50 times higher than the recommended daily allowance every day for a month, investigators say
Proposed Changes of USP <797> Strengthens Documentation Requirements
Once the revisions to <797> become approved, there will be a minimum grace period of 6 months for pharmacies to comply.
USP <800> Will Become Enforceable for Facilities Once Revisions of <795>, <797> Approved
Kevin Straughn, PharmD, clinical pharmacist at Duke Regional Hospital, said once the 2 compounding chapters, <797> and <795> become enforceable, there will be a 6-month grace period before USP <800> becomes enforceable.
An Overview of Antimicrobials in Pneumonia Pharmacotherapy
The most common way to detect bacteria and determine the right medication to use is with the gram stain test, which will show whether the bacteria is gram-positive or gram-negative
Knowing Personal Value is Key for Pharmacy Technicians to Advance Their Career
Seeking personal fulfillment over money can help when assessing one’s value as a pharmacy technician.
PrEP Delivery Remains Low Among Those With Opioid/Stimulant Use Disorder
Preexposure prophylaxis should be consistently offered alongside HIV prevention services and treatment for substance abuse, investigators say.
AbbVie Files Migraine Prevention Drug Atogepant in European Union
The submission is based on 2 pivotal phase 3 studies evaluating the drug in adult patients with chronic and episodic migraines.
Treatment With Adagrasib Shows Intracranial Response in Patients With Lung Cancer, Untreated CNS Metastases
Approximately one-third of the individuals had an intracranial response among those with central nervous system metastases.
Study Results Suggest C. Difficile Drives Some Colorectal Cancers
Analysis shows that the common infection may be a driver of the disease in adults younger than aged 50 years.
Roche Launches Dual Antibody, Antigen Hepatitis C Virus Diagnostic Test
Elecsys HCV Duo allows independent and simultaneous determination of early-stage infection and those who are recovering or showing signs of a chronic problem.
Study: Y Chromosome Loss in Men Increases Risk of Heart Failure, Death From CVD
Results are first to show causal relationship between losing mLOY in the blood and development of cardiovascular disease.
Study Results Show Moderate Drinking May Cause Cognitive Decline
Data indicate that consumption of 7 or more units of alcohol per week is associated with higher iron levels in the brain, which has been linked to Alzheimer and Parkinson diseases.
Hemlibra Continues to Demonstrate Favorable Profile for Individuals with Hemophilia A
Data from Roche’s phase 3 HAVEN 6 study show clinically meaningful bleed control, with no new safety signals observed.
Dupixent Trial Shows Positive Results in Younger Children With Eosinophilic Esophagitis
Phase 3 study follows recent approval of the drug for the same condition in individuals aged 12 years and older who weight at least 40 kg.
New Data on Adagrasib Show Regression of CNS Metastases in KRASG12C-mutated NSCLC
About one-third of participants in the phase 1b cohort of the KRYSTAL-1 study show an intracranial response, according to Mirati Therapeutics.
Merck Announced Positive Study Results Evaluating V116 Pneumococcal Vaccine
The investigational PCV is designed to target serotypes responsible for 85% of all invasive cases of the disease in individuals aged 65 and older in the United States.
Study Finds Attitudes Around Older Motherhood Focus on Negative Outcomes
Investigators argue that much of the language around women who give birth later in life is rooted in ableism and ageism and is out of step with current childbirth trends.
FDA Approves Bludigo Injection for Visualization Aid in Assessment of the Ureters
Provepharm filed its application with the agency in September 2021, and, with the new approval, its US affiliate will market the product directly in the United States.
Study Shows Positive Data on Pair of Omicron-Adapted COVID-19 Vaccine Candidates
A booster dose of both Omicron-adapted vaccine candidates elicited a substantially higher immune response against Omicron BA.1.
Study: Light During Sleep in Older Adults Is Linked to Diabetes, High Blood Pressure, Obesity
Study results show that there is a link between leaving the television on, night lights, and smart phones and higher disease rates.
Ofatumumab Shows Long-Term Improvements in Multiple Sclerosis Disease Activity
After 4 years of treatment with ofatumumab, 78.8% of patients with relapsing forms of multiple sclerosis who continuously received ofatumumab achieved NEDA-3 compared to 51.8% of those who switched from teriflunomide to ofatumumab.
Gilead Resubmits NDA for Lenacapavir, Updates Based on FDA Complete Response Letter
Lenacapavir is an investigational, long-acting HIV-1 capsid inhibitor that is not yet approved by any regulatory authority.
Sativex Does Not Meet Primary Endpoint on Measures of Spasticity for Multiple Sclerosis
Jazz Pharmaceuticals announced top-line results from the phase 3 RELEASE MSS1 trial, evaluating nabiximols oromucosal spray in individuals with multiple sclerosis.
2 Clarke Drive Cranbury, NJ 08512